GleamWall
中文EN

ANTX AN2 Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1880438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.5%
TTM EPS YoY19.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.3%
ROA-46.7%
ROIC (approx.)-60.6%
Asset turnover—

Leverage & solvency

Liabilities / assets7.9%
Debt / equity0.00x
Current ratio10.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$24.77M$40.49M
SG&A expense$13.34M$14.07M
Operating income-$38.11M-$56.79M
Income tax$0$0
Net income-$35.17M-$51.32M
EPS (basic)-1.16-1.72
EPS (diluted)-1.16-1.72
Weighted avg. shares (diluted)30.22M29.83M
Balance sheet
Cash & equivalents$19.94M$21.35M
Short-term investments$38.06M$62.27M
Current assets$59.94M$86.26M
Total assets$61.95M$92.09M
Current liabilities$8.72M$10.24M
Total liabilities$8.89M$10.24M
Shareholders' equity$53.06M$81.85M
Shares outstanding27.41M29.92M
Cash flow statement
Operating cash flow-$29.83M-$49.26M
Investing cash flow$28.31M$54.59M
Financing cash flow$113,000$372,000
Stock-based compensation$6.25M$8.34M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.